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Role of adipose tissue GLP-1R 
expression in metabolic 
improvement after bariatric surgery 
in patients with type 2 diabetes
Miriam ejarque  1,2, Fernando Guerrero-pérez3, Nuria de la Morena1,2, Anna Casajoana4, 
Nuria Virgili3, Rafael López-Urdiales3, Elsa Maymó-Masip1,2, Jordi pujol Gebelli4, 
Amador Garcia Ruiz de Gordejuela4, Manuel perez-Maraver3, Silvia pellitero2,5, 
sonia Fernández-Veledo  1,2, Joan Vendrell1,2 & Nuria Vilarrasa2,3
We aimed to explore the relationship between GLP-1 receptor (GLP-1R) expression in adipose tissue 
(AT) and incretin secretion, glucose homeostasis and weight loss, in patients with morbid obesity and 
type 2 diabetes undergoing bariatric surgery. RNA was extracted from subcutaneous (SAT) and visceral 
(VAT) AT biopsies from 40 patients randomized to metabolic gastric bypass, sleeve gastrectomy or 
greater curvature plication. Biochemical parameters, fasting plasma insulin, glucagon and area under 
the curve (AUC) of GLP-1 following a standard meal test were determined before and 1 year after 
bariatric surgery. GLP-1R expression was higher in VAT than in SAT. GLP-1R expression in VAT correlated 
with weight (r = −0.453, p = 0.008), waist circumference (r = −0.494, p = 0.004), plasma insulin 
(r = −0.466, p = 0.007), and systolic blood pressure (BP) (r = −0.410, p = 0.018). At 1 year, GLP-1R 
expression in VAT was negatively associated with diastolic BP (r = −0.361, p = 0.039) and, following 
metabolic gastric bypass, with the increase of GLP-1 AUC, (R2 = 0.46, p = 0.038). Finally, GLP-1R in AT 
was similar independently of diabetes outcomes and was not associated with weight loss after surgery. 
Thus, GLP-1R expression in AT is of limited value to predict incretin response and does not play a role in 
metabolic outcomes after bariatric surgery.
Glucagon-like peptide-1 (GLP-1) is a potent stimulator of glucose-dependent insulin secretion, and also confers 
beneficial actions on gastric emptying and appetite regulation1–3. GLP-1 exerts its effects principally through its 
interaction with the G protein-coupled receptor GLP-1R, which in humans is broadly expressed in the central 
nervous system and in peripheral tissues such as pancreas, heart, kidney, gastrointestinal tract and adipose tissue 
(AT)4. However, the extrapancreatic mechanisms and actions of GLP-1, especially in AT, remain insufficiently 
understood5–9. Accumulated data from in vitro studies in rat and human cell lines have described both lipogenic 
and lipolytic activity for GLP-1 that seems to be dependent on its concentration5–8,10–12. Moreover, studies in 
murine 3T3-L1 preadipocytes indicated that GLP-1 promotes pre-adipocyte differentiation and inhibition of 
apoptosis13–15. Interestingly, GLP-1R has been recently implicated in energy metabolism by directly stimulating 
mitochondrial bioenergetics and brown AT remodeling16,17. Some authors have hypothesized that promotion of 
adipogenesis through activation of GLP-1R increases the capacity of visceral hypertrophic adipocytes to store 
lipids, thereby decreasing ectopic lipid accumulation and improving insulin resistance (IR)18. In humans, GLP-1R 
expression was increased in visceral AT (VAT) from morbid obese subjects with a high insulin-resistant profile 
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as compared with insulin-sensitive lean, overweight, and low insulin-resistant obese groups8. Furthermore, high 
GLP-1R expression in VAT predicted a greater improvement in the systemic IR index after biliopancreatic diver-
sion surgery8.
In view of the aforementioned observations and considering that VAT dysfunction has been classically linked 
to inflammation and IR19–21, then it does not seem unreasonable to predict an additional role for this incretin 
receptor in AT metabolic functions, which might influence the recovery of glucose homeostasis and IR after 
massive weight loss. Accordingly, the aim of the present study was to explore the relationship between GLP-1R 
expression in AT and incretin secretion, glucose homeostasis, metabolism and weight loss after bariatric surgery. 
To do this, we used a well-characterized cohort of patients with morbid obesity and type 2 diabetes mellitus (T2D) 
undergoing bariatric surgery in the setting of a randomized controlled trial (RCT).
Matherial and Methods
Study design and setting. This study was part of a prospective single centre, non-blinded RCT, including 
patients with morbid obesity and T2D undergoing bariatric surgery. The trial was registered on January 25, 2016 
at www.controlled-trials.com (ISRCTN14104758). Patients were consecutively recruited from the diabetes outpa-
tient clinic of Bellvitge University Hospital, Barcelona, Spain. The study was conducted according to the principles 
of the Declaration of Helsinki. All patients signed an informed consent and the protocol study (PI11/01960) was 
approved by the Clinical Research Ethics Committee of Bellvitge University Hospital (reference PR 143/11).
The inclusion criteria were age between 18 and 60 years, body mass index (BMI) 35–43 kg/m2, T2D on hypo-
glycemic agents alone, insulin, or both. The exclusion criteria were the following: type 1 diabetes or positivity for 
glutamic acid decarboxylase autoantibodies, secondary forms of diabetes, acute metabolic complications, liver 
disease, renal dysfunction or patients under anticoagulant treatment, previous bariatric surgery, congenital or 
acquired abnormalities of the digestive tract, pregnancy, nursing or desired pregnancy in the 12 months follow-
ing inclusion, and corticoid use by oral or intravenous route for more than 14 consecutive days in the last three 
months.
Randomization. Patients were randomly assigned 1:1:1 to undergo metabolic Roux-en-Y gastric bypass 
(mRYGB), sleeve gastrectomy (SG) or greater curvature plication (GCP). The randomization process was per-
formed by the statistics department at Bellvitge University Hospital. A computer random number generator with 
opaque sealed sequentially numbered envelopes with stratification according to baseline levels of HbA1c (greater 
or lower/ equal to 7%) was used.
Study protocol. In the mRYGB procedure, a 100-mL gastric pouch is created along with a 200-cm bilio-
pancreatic limb and an alimentary limb of 100 cm. SG is a restrictive technique consisting of a gastric volume 
reduction of 75–80% by resecting the stomach over a 36-French catheter beginning 4 cm from the pylorus and 
ending at the angle of His. GCP is a reversible restrictive technique with no stomach resection, in which an 
invagination of the greater gastric curvature is performed with two running non-absorbable sutures, calibrated 
over a 36-French catheter. A physical examination with determination of anthropometrical parameters and a 
complete biochemical analysis was performed before bariatric surgery and at months 1, 3, 6, and 12 following the 
procedure.
Buse’s criteria were used to define T2D remission in each procedure at 1 year of follow-up: Complete remis-
sion = HbA1c < 6% and fasting glucose < 100 mg/dl (<5.6 mmol/l) with no diabetes drugs for 1 year; partial 
remission = HbA1c < 6.5% and fasting glucose < 100–125 mg/dl (5.6–6.9 mmol/l) with no diabetes drugs for 1 
year22.
Anthropometric measurements. Body weight, height and waist circumference, and blood pressure were 
measured at every visit. Weight change after surgery was reported as total weight loss percentage (TWL%) [(pre-
operative weight − current weight)/(preoperative weight) × 100]. Body composition was analysed by dual-energy 
X-ray absorptiometry (Hologic QDR 4500; Hologic Inc., Waltham, MA) before and 12 months after surgery.
Standard meal test. The standard meal test (SMT) was performed before bariatric surgery and at months 
1 and 12. The SMT consisted of 200 ml of a liquid meal (Edanec®) containing 54% carbohydrates, 16% proteins, 
and 30% lipids, equivalent to 1 kcal/ml. Incretin-related treatments were discontinued at least 1 month before 
the analysis; the remainder of diabetes treatments, excluding insulin, were withdrawn at least 1 week before the 
SMT. Blood was drawn immediately before and 15, 30, 60 and 120 minutes following the SMT for determination 
of GLP-1 concentration23. Fasting glucagon levels were determined before the SMT. There were no changes to 
methods after trial commencement.
Laboratory determinations. Glucose, cholesterol and triglycerides were determined using standard 
enzymatic methods. Plasma insulin was analysed by immunoassay (Coat-A-Count Insulin; Diagnostic Products 
Corp., Los Angeles, CA); inter- and intra-assay variability was 6.6–12.4% and 5.8–21.7%, respectively. GLP-1 was 
measured by radioimmunoassay (Millipore, Saint Charles, MO); inter and intra-assay variability was 10–23% 
and 22–38%, respectively. To obtain complete dipeptidyl peptidase IV inhibition, all samples were processed 
with a DPP-IV inhibitor (DPP4–010; Merck, Madrid, Spain). Glucagon was measured by enzyme immunoassay 
(Yanahaira Institute Inc., Awakura, Fujinomiya-shi Shizuoka, Japan).
Gene expression analysis. Total RNA was extracted from subcutaneous AT (SAT) and VAT biopsies 
obtained during surgery using the RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA). One microgram of RNA 
was reverse transcribed with random primers using the reverse transcription system high capacity cDNA kit 
(Applied Biosystems, Foster City, CA). Quantitative GLP-1R expression was evaluated with Taqman low-density 
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arrays (Hs00157705_m1; Applied Biosystems microfluidic cards) on a 7900HT Fast Real-Time PCR platform. The 
relative expression was measured using the 2−ddCt method. Peptidyl-prolylisomerase A (PPIA, Hs04194521_s1) 
was used for normalization of gene expression levels and calculation of dCt values due to its stability across tissues 
and samples24,25.
Outcomes. The primary outcome of the study was the predictive value of gut hormone dynamics (GLP-1, 
glucagon, peptide-YY [PYY] and ghrelin) on glucose metabolism improvement at 1 and 12 months after surgery 
for each procedure. The study had two main secondary outcomes. The first was to compare the rate of T2D remis-
sion in each procedure at 1 year of follow-up, defined by Buse’s criteria22. The results of the previous primary and 
secondary outcomes have been published26. The other secondary outcome was the determination of the role of 
GLP-1 R expression in AT in incretin response, weight loss, insulin sentivity improvement and diabetes remission 
after surgery. There were no changes to trial outcomes after commencement of the study.
Statistical analysis. Based on preliminary data, the study was designed to detect a 20% difference in GLP-1 
secretion (measured by the area under the curve [AUC] after the SMT) before and 1 month after bariatric surgery, 
with a power of 80% and α risk of 0.05. At least 10 subjects per group were considered, but to account for the 
possibility of loss at follow-up 15 patients per group were finally assigned. Biochemical and hormonal parameters 
were compared between procedures by analysis of variance (ANOVA). Categorical variables were compared using 
the Chi-square test and quantitative variables using ANOVA or the Kruskal-Wallis test. GLP-1R mRNA expres-
sion data were log transformed for analysis. GLP-1 AUC was calculated by the trapezoidal method27. Bivariate 
(Pearson or Spearman) and multivariate regression analyses were employed to determine the associations of 
GLP-1R expression in SAT and VAT with glucose, lipid profile, IR and incretin concentration. Moreover, the asso-
ciation of GLP-1R expression with T2D remission, homeostasis model assessment (HOMA)-IR and HOMA-β, 
weight loss and incretin secretion at 1 year was also tested. As this was an exploratory study, we did not make 
adjustments for multiple comparisons as the use of more stringent criteria could increase the likelihood of miss-
ing clinically significant associations between variables. Statistical analysis was performed using R software ver-
sion 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). A P-value < 0.05 was considered statistically 
significant.
Results
From May 2012 to February 2014, 45 morbidly obese patients with T2D, aged 49.4 ± 7.9 years, BMI 39.4 ± 1.9 kg/m2, 
initial HbA1c 7.7 ± 1.9%, were consecutively randomized to mRYGB, SG or GCP (n = 15 in each group). All 
patients completed the study with the exception of one patient allocated to the SG group who withdrew from the 
study after 10 months. Paired samples from SAT and VAT were obtained during surgery in 40 patients (n = 15 
mRYGB, n = 13 SG and n = 12 GCP), and all patients completed the 12 months study period. Baseline clinical and 
biochemical characteristics of the 40 patients are listed in Table 1.
As a summary of previously published data26, TWL% was significantly greater in the mRYGB group than in 
SG and GCP groups at 12 months: −35.29 ± 8.17 vs. −27.26 ± 5.66 vs. −20.24 ± 7.49%, respectively, p < 0.05. 
At 1 year of follow-up, HbA1c was significantly lower in the mRYGB group than in the SG and GCP groups: 5.09 
(0.62) vs. 6.24 (0.85) vs. 6.79 (1.39) %, respectively, p < 0.05. After surgery, the increase in the AUC for GLP-1was 
significantly higher in the mRYGB group than in SG and GCP groups: 87.3 [6.21;163] vs. 22.2 [2.40;32.9] vs. 
−0.28 [−23.94;40.5], respectively, p < 0.05. Short-term complete diabetes remission at 1 year was found in 80% 









Number of patients 15 13 12
Sex (male/female) 7/8 4/9 2/10 0.301
Age, yr 51.10 (7.70) 48.20 (9.47) 49.60 (8.94) 0.692
Weight, kg 103 (10.8) 103 (11.2) 105 (13.2) 0.883
Body mass index, kg/m2 38.7 (2.01) 39.3 (1.42) 40.4 (1.35) 0.037*
Waist circumference, cm 118 (7.58) 118 (7.99) 117 (8.48) 0.878
Total body fat, % 38.4 [28; 43] 35.8 [31; 37] 37.8 [36; 41] 0.301
T2D duration, months 54 [39.5–114] 120 [51.2–180] 83 [45–144] 0.216
C-peptide, ng/ml 3.04 ± 1.01 3.13 ± 1.80 3.75 ± 2.75 0.566
Fasting glucose, mmol/l 8.38 (3,00) 1.08 (0.64) 1.26 (1.00) 0.639
HbA1c, % 7.39 (1.95) 7.94 (1.79) 8.47 (2.19) 0.377
Insulin treatment, %, (n) 33.30 (5) 38.5 (5) 58.3 (7) 0.400
Dyslipidemia, %, n 73.3 (11) 84.6 (11) 91.7 (11) 0.518
Hypertension, %, n 66.7 (10) 69.2 (9) 75.0 (9) 0.912
Table 1. Baseline characteristics of patients. Data are expressed as mean ± SD for normally distributed variables 
and median [interquartile range] for non-normally distributed variables. *p < 0.05 was considered statistically 
significant. T2D: type 2 diabetes; HbA1c: glycated hemoglobin A1c.
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Analysis of GLP-1R expression in AT biopsies at surgery revealed a higher expression of the receptor in the 
visceral than in the subcutaneous depots (Fig. 1). Nonetheless, when we analysed GLP-1R expression in relation 
to patients’ baseline characteristics, VAT GLP-1R expression was inversely correlated with weight (r = −0.453, 
p = 0.008) and waist circumference (r = −0.494, p = 0.004), indicating that patients with greater weight and waist 
circumference had lower GLP-1R expression in this depot (Fig. 2). No association was found between GLP-1R 
expression in VAT and other anthropometrical parameters such as body fat or BMI. Regarding biochemical 
parameters, VAT GLP-1R expression was inversely correlated with basal plasma insulin (r = −0.466, p = 0.007), 
indicating that patients with higher insulin concentrations had lower GLP-1R expression. No differences in VAT 
GLP-1R expression were found with glucose metabolism parameters (glucose and HbA1c), HOMA-IR, HOMA-β 
or lipid profile. Similarly, there was no correlation between VAT GLP-1R expression and pre-surgical GLP-1 AUC 
in plasma or fasting glucagon concentrations. Regarding blood pressure, VAT GLP-1R expression was inversely 
correlated with systolic blood pressure (r = −0.410, p = 0.018) (Table 2). A multivariate regression analysis to 
account for confounders was performed finding that VAT GLP-1R expression remained inversely correlated with 
weight (R2 = 0.223, p = 0.049) after adjusting for gender, BMI, insulin and HbA1c. Analysis of GLP-1R expression 
in SAT showed no significant associations with anthropometrical, biochemical or hormonal parameters.
Figure 1. Comparison of GLP-1R expression in visceral (VAT) and subcutaneous (SAT) adipose tissue.
Figure 2. Correlative analysis of GLP-1R mRNA expression in visceral (VAT) with waist circumference before 
and 12 months after surgery. The correlations were determined by Pearson’s correlation coefficient test (r).
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When we analysed AT GLP-1R expression using parameters at 12 months after surgery, we found an inverse 
association between GLP-1R expression in VAT and diastolic blood pressure at 12 months (r = −0.361, p = 0.039), 
however this correlation lost significance in the multivariate regression analysis after adjusting for gender, BMI, 
HbA1c and type of surgery. No other correlations were found between VAT or SAT GLP-1R expression in the 
bivariate and multiple regression analysis and glucose metabolism parameters or lipid profile at 12 months 
(Table 3), or with their changes after the intervention.
Regarding the association between GLP-1R expression in AT and GLP-1 concentration, only those patients 
undergoing mRYGB, characterized by a greater metabolic improvement and higher incretin response, showed a 
negative relationship between GLP-1R expression in VAT and the increase of GLP-1 AUC at 1 year after surgery 
(r = −0.670, p = 0.015). In multiple regression analysis, VAT GLP-1R expression after mRYGB remained inversely 
associated with the increase of GLP-1 AUC at 1 year after surgery, after adjusting for changes in weight, BMI and 
HbA1c (R2 for the model 0.46, p = 0.038). However, GLP-1R expression in AT did not predict metabolic outcomes. 
Accordingly, no correlations were observed between GLP-1R expression in AT and glucose, HbA1c or insulin 
sensitivity improvement calculated by HOMA-IR or HOMA-β after the intervention. Moreover, GLP-1R expres-
sion at VAT and SAT did not differ between patients remaining with T2D compared with those under partial or 
complete T2D remission after the bariatric procedure: 0.29 (0.04;0.82) vs. 1.05 (0.22;2.10) vs. 0.28 (0.08;2.18), 
p = 0.779 and 0.02 (0.0009;0.007) vs. 0.03 (0.0026;0.32) vs. 0.17 (0.01;0.37), p = 0.278, respectively (Fig. 3). Finally, 
GLP-1R expression in AT was not associated with weight response after surgery.
GLP-1 R in VAT GLP-1 R in SAT
R p-value R p-value
Weight −0.453 0.008* −0.121 0.495
Glucose 0.069 0.703 −0.385 0.240
HOMA-IR −0.198 0.276 −0.210 0.241
HbA1c −0.169 0.347 −0.132 0.457
C-peptide 0.148 0.412 −0.078 0.660
Glucagon −0.101 0.575 −0.109 0.539
GLP-1 AUC 0.300 0.108 −0.034 0.860
Total cholesterol 0.036 0.841 −0.094 0.598
HDL cholesterol 0.047 0.796 −0.054 0.761
LDL cholesterol −0.188 0.347 −0.009 0.963
Triglycerides 0.197 0.272 0.063 0.725
sBP −0.410 0.018* 0.094 0.597
dBP −0.313 0.076 0.041 0.817
Table 2. Bivariate correlations between GLP-1R expression in visceral (VAT) and subcutaneous (SAT) adipose 
tissue and baseline plasma metabolic and hormonal parameters. HOMA-IR: homeostasis model assessment 
insulin resistance; GLP-1 AUC (area under the curve for GLP-1); HbA1c: glycated hemoglobin A1c; sBP: systolic 
blood pressure; dBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein. 
*p < 0.05 was considered statistically significant.
GLP-1 R in VAT GGLP-1 R in SAT
R p-value R p-value
Weight −0.205 0.253 0.047 0.793
Glucose −0.110 0.541 −0.067 0.705
HOMA-IR −0.023 0.899 −0.295 0.096
Insulin −0.067 0.717 −0.032 0.858
HbA1c 0.062 0.734 −0.179 0.311
GLP-1 AUC −0.119 0.524 0.117 0.516
Total cholesterol 0.140 0.438 0.008 0.963
HDL cholesterol 0.170 0.345 −0.027 0.879
LDL cholesterol −0.079 0.680 −0.014 0.939
Triglycerides 0.134 0.457 0.045 0.799
sBP −0.219 0.221 0.054 0.762
dBP −0.361 0.039* 0.199 0.259
Table 3. Bivariate correlations between GLP-1R expression in visceral (VAT) and subcutaneous (SAT) adipose 
tissue and plasma metabolic and hormonal parameters measured 12 months after bariatric surgery. HOMA-IR: 
homeostasis model assessment insulin resistance; GLP-1 AUC (area under the curve for GLP-1); HbA1c: 
glycated hemoglobin A1c; sBP: systolic blood pressure; dBP: diastolic blood pressure; HDL: high-density 
lipoprotein; LDL: low-density lipoprotein. *p < 0.05 was considered statistically significant.
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Discussion
In the present study, we evaluated the clinical significance of GLP-1R expression in AT in relation to plasma 
incretin concentration, glucose homeostasis, insulin sensitivity improvement and weight outcome in patients 
with T2D undergoing bariatric surgery in an RCT. In subjects randomized to mRYGB, basal GLP-1R expression 
in VAT was an inverse determinant of the increase in incretin concentration after surgery. However, GLP-1R 
expression in AT was not associated with diabetes remission or weight loss after surgery.
GLP-1R is broadly expressed in many tissues beyond the pancreas, including lung, brain, stomach, heart, 
kidney, endothelium, bone and also AT4. The physiological actions of GLP-1R have been well documented over 
the last decade, especially after the extensive clinical applications of GLP-1 mimetics for diabetes, such as GLP-1R 
agonists and DPP-4 inhibitors1,2. However, the significance of GLP-1R in AT is not fully understood and remains 
contentious. Data from in vitro studies indicate that GLP-1 has a role in adipogenesis5–15. Murine 3T3-L1 adi-
pocyte precursors treated with GLP-1 and exendin-4 (a GLP-1R agonist) showed increased differentiation14, 
favouring intracellular lipid accumulation and insulin-mediated glucose uptake through up-regulation of Glut-4 
expression and phosphorylation of the insulin receptor in adipocytes28. While the evidence is less established in 
humans, in mature adipocytes GLP-1 treatment induced a significant lipolytic effect in a dose-dependent man-
ner8,12. More recently, treatments with GLP-1 analogues have been associated with increased proliferation and 
inhibition of apoptosis in human adipose-derived stromal cells29, and also with stimulation of mitochondrial 
bioenergetics in AT16,17.
In addition to mature adipocytes, AT also contain various cell populations in the stromal vascular fraction 
(SVF), including mesenchymal stem cells (MSCs), preadipocytes, fibroblasts, vascular endothelial cells, and a 
range of immune cells such as AT macrophages. GLP-1R has been found expressed in mature adipocytes and 
MSCs, but the expression in the rest of SVF components remain elusive8. The GLP-1R agonist exendin-4 is able to 
inhibit LPS-induced TNF-α expression in macrophages, which is an indirect evidence of the anti-inflammatory 
role of GLP-1 in macrophages30. Also, inhibition of nuclear factor-kappa B (NF-κB) activation of macrophage 
population in AT in the presence of GLP-1R analogs has been reported31. Furthermore, endothelial vascular cells 
are sensitive to the GLP1-R analogs, with a net anti-inflammatory effect through different molecular mechanisms 
driven by the activation of adenosine monophosphate-activated protein kinase (AMPK)32. Altogether, previous 
data would suggest that GLP-1R expression within AT is due to the contribution of its two major components, 
mature adipocytes and the cellular components of the SVF, with a predominant anti-inflammatory effect in the 
last location.
GLP-1R expression has been described in AT of lean subjects, with higher expression in visceral than in sub-
cutaneous depots, and with lower expression than in insulin-resistant morbidly obese subjects8. In line with a 
previous report, we observed higher expression of GLP-1R in VAT than in SAT compartments8. Consistent with 
this, a recent study identified GLP-1R expression in epicardial AT, which represents the visceral fat equivalent of 
the heart33. Interestingly, an excess of epicardial fat has been implicated in IR and cardiovascular diseases, exert-
ing its atherogenic action through the paracrine secretion of pro-inflammatory cytokines34. Similarly, an increase 
in abdominal VAT is associated with an increased metabolic, cardiovascular risk and greater mortality prediction 
capacity20,21,35. Many of these deleterious events are mediated, in part, by inflammatory mechanisms originating 
in the AT depots. Indeed, recent data suggest that GLP-1-based therapies may have anti-inflammatory effects 
Figure 3. Comparison of GLP-1R expression in visceral (VAT) and subcutaneous (SAT) adipose tissue and 
diabetes outcomes 12 months after surgery.
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in several organs including AT, by reducing the production of pro-inflammatory cytokines and infiltration of 
immune cells31,36. Therefore, improving the knowledge of the regulatory dynamics of the GLP1/GLP-1R axis in 
AT might have relevance for the treatment of local and systemic inflammatory events in obesity and T2D.
In patients with morbid obesity without T2D, the expression of GLP-1R in VAT has been described to be pos-
itively associated with the degree of IR and with the greatest insulin sensitivity improvement after biliopancreatic 
diversion surgery8. While our results in patients with T2D support this association, our findings revealed a neg-
ative correlation between insulin levels and GLP-1R expression in VAT. This is consistent with the negative rela-
tionship observed between weight, waist circumference and blood pressure and GLP-1R expression in this depot; 
thus, the greater the metabolic disturbances the lower the GLP-1R expression in AT. It should be highlighted that 
our cohort comprised patients with morbid obesity and T2D, and this may result in a different behaviour when 
compared with euglycemic subjects. Indeed, to the best of our knowledge, this is the first study to analyse the 
GLP-1/GLP-1R axis in AT of subjects with these characteristics. Our results lead us to speculate that our patient 
cohort might present disrupted GLP-1/GLP-1R signalling, resulting in a decrease in GLP-1 sensitivity in AT. This 
hypothesis might explain why those patients with greater BMI and levels of insulin, who would be expected to 
have the lowest circulating GLP-1 concentrations and a higher expression of the receptor, showed the opposite; 
that is, a lower receptor expression at the VAT level.
Regarding the relationship between GLP-1R expression in AT and GLP-1 concentration/secretion, we were 
unable to find an association before surgery. However, in subjects who underwent mRYGB, who showed the 
greatest incretin response after surgery, GLP-1R expression in AT negatively predicted the increase in GLP-1 con-
centration after the procedure. Although this finding has to be interpreted with caution due to the small sample 
size, it might suggest the existence of a regulatory feedback between GLP-1 secretion and GLP-1R expression in 
VAT. The absence of an association in the other bariatric procedures could be due to the lower improvement in 
the incretin response observed in non-derivative surgeries.
GLP-1R has been associated with both lipogenic and lipolytic activity5–15. In the present study, however, no 
association was found between GLP-1R expression and plasma lipid profile before or after surgery. Nevertheless, 
we only determined plasma circulating lipids and not intra-adipocyte lipolysis.
Many hormonal and clinical factors have been implicated in glucose improvement and weight loss after bari-
atric surgery37–39. To our knowledge, however, this is the first study analysing the predictive value of pre-surgery 
GLP-1R expression in AT on glucose metabolism and weight outcomes after different bariatric procedures. But, 
despite its potential relationship with incretin secretion, no association was found between GLP-1R expression in 
AT and either diabetes remission, insulin resistance improvement or weight loss after surgery.
We are aware that the study has some limitations. The limited number of subjects included and the low 
GLP-1R expression levels detected may reduce the strength of our observations. Moreover, the fact that AT biopsy 
samples were only available during surgery, and not afterwards, prevents the evaluation of GLP-1R expression 
changes with metabolic improvement after bariatric surgery, thus limiting our results. Also, we could only analyse 
glucagon concentrations in the fasting state, and so we could not calculate the AUC for this hormone, which is a 
more reliable indicator of its secretion. As our study was exploratory, further additional dedicated studies should 
be conducted in larger cohorts with pre-planned hypotheses and higher statistical power to confirm the observed 
associations.
Conclusions
In subjects with morbid obesity and T2D, GLP-1R expression in AT is of limited value to predict incretin response 
and does not play a role in metabolic outcomes such as insulin sensitivity improvement, T2D remission and 
weight loss after bariatric surgery. Further studies are warranted to explore a possible paracrine role of this recep-
tor in AT.
Data Availability
All data analysed during this study is included in this article as well as in a previous published article cited in the 
references. If any further information is required please contact the corresponding author.
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